FSD Pharma Inc
CNSX:HUGE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
FSD Pharma Inc
Net Income
FSD Pharma Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
FSD Pharma Inc
CNSX:HUGE
|
Net Income
-$18.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-203%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Income
$120m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Net Income
-CA$326.6m
|
CAGR 3-Years
53%
|
CAGR 5-Years
33%
|
CAGR 10-Years
-72%
|
|
|
Cronos Group Inc
TSX:CRON
|
Net Income
-$2.9m
|
CAGR 3-Years
74%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Net Income
-$168.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-112%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Income
-CA$5.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
FSD Pharma Inc
Glance View
FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. The company is headquartered in Toronto, Ontario and currently employs 10 full-time employees. The company went IPO on 2018-05-29. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its lead compound, FSD 201, ultra-micronized Palmitoyl (PEA). FSD 201 stabilizes mast cells of the human body and down-regulate the proinflammatory cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a subsidiary of the Company, has worldwide rights to compounds shown to prevent and reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, the Company is focused on develop a psychoactive (psychedelic-based) therapeutic of neurodegenerative disorders.
See Also
What is FSD Pharma Inc's Net Income?
Net Income
-33.9m
USD
Based on the financial report for Dec 31, 2021, FSD Pharma Inc's Net Income amounts to -33.9m USD.
What is FSD Pharma Inc's Net Income growth rate?
Net Income CAGR 5Y
-203%
Over the last year, the Net Income growth was -19%. The average annual Net Income growth rates for FSD Pharma Inc have been -26% over the past three years , -203% over the past five years .
